Company: TELO
Filing Date: 2025-02-14
Form Type: S-3
Source: 0001493152-25-006943
Chunk: 27

Company: Telomir Pharmaceuticals, Inc.
Filing Date: 2025-02-14
Form: S-3
Chunk 27
---
 the last reported sale price of our common stock on the Nasdaq Capital Market was $4.25 per share.

Neither the Securities and Exchange Commission nor any state securities commission has approved or disapproved of these securities or passed upon the adequacy or accuracy of this prospectus. Any representation to the contrary is a criminal offense.

<div align='center'>Rodman & Renshaw LLC

The date of this prospectus is</div>

<div align='center'>TABLE OF CONTENTS

PROSPECTUS</div>

|                                                   | Page   |
| ABOUT THIS PROSPECTUS                             | Alt-1  |
| PROSPECTUS SUMMARY                                | Alt-2  |
| THE OFFERING                                      | Alt-4  |
| RISK FACTORS                                      | Alt-5  |
| SPECIAL NOTE REGARDING FORWARD-LOOKING STATEMENTS | Alt-11 |
| USE OF PROCEEDS                                   | Alt-13 |
| DILUTION                                          | Alt-14 |
| DIVIDENDS                                         | Alt-15 |
| PLAN OF DISTRIBUTION                              | Alt-15 |
| LEGAL MATTERS                                     | Alt-16 |
| EXPERTS                                           | Alt-16 |
| WHERE YOU CAN FIND MORE INFORMATION               | Alt-17 |
| INCORPORATION OF CERTAIN INFORMATION BY REFERENCE | Alt-17 |

<div align='center'>ABOUT THIS PROSPECTUS</div>

This prospectus is part of a registration statement on Form S-3 that we filed with the Securities and Exchange Commission using a “shelf” registration process. This prospectus relates to the offering of our common stock. Before buying any of the common stock that we are offering, we urge you to carefully read this prospectus, together with the information incorporated by reference as described under the heading “Where You Can Find More Information” and “Incorporation of Certain Information by Reference.” These documents contain important information that you should consider when making your investment decision.

This prospectus describes the specific terms of the common stock we are offering and also adds to and updates information contained in the documents incorporated by reference into this prospectus. To the extent there is a conflict between the information contained in this prospectus, on the one hand, and the information contained in any document incorporated by reference in this prospectus, on the other hand, you should rely on the information in this prospectus. If any statement in one of these documents is inconsistent with a statement in another document having a later date—for example, a document incorporated by reference